Biofrontera received manufacturing and distribution license
Biofrontera AG announces, that its subsidiary Biofrontera Pharma GmbH received the permission to import pharmaceutical products, clear them for European sales and distribute them.
The responsible district government has inspected the Company, assessing all requirements for granting the manufacturing and distribution license in accordance with the German pharmaceutical law. Biofrontera has sufficient qualified personnel, appropriate rooms and facilities as well as a complex quality management system for importing, approving, storing and distributing pharmaceutical compounds.
The manufacturing license is needed for the European submission of the marketing authorization of BF-200 ALA, planned for the beginning of September. By obtaining the license Biofrontera fulfils another important precondition for a marketing authorization application in the centralized European procedure.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Santhera Provides Update on Clinical/Regulatory Processes with SNT-MC17/Idebenone for the Treatment of Friedreich's Ataxia
Cipher reaches agreement to dismiss patent litigation in United States for CIP-Fenofibrate
Genomatix met cash-flow break-even in 2003
Breakthrough at Ark opens way to reduce side-effects and increase efficacy of anti-cancer therapies - Unique DNA-based targeting technology Scavidin halts tumour progression with one-tenth of conventional chemotherapy dose
BioFocus and Almac collaborate to offer fluorescent lifetime assays
Genentech to set up Singapore's first Microbial-Based Biopharmaceutical Manufacturing Facility - Fourth Biologics Facility in Less Than 2 Years Helps Establish Singapore as a Serious Player in Biologics Manufacturing
Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome
ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer
Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture
Researchers identify genes linked to chemoresistance
